ストックスクリーナーアプリを入手
3.4369
0.72%
-0.0231
Esperion Therapeutics Inc (ESPR) 最新ニュース
New hires at Esperion receive 40,200 restricted stock units as hiring incentive - Stock Titan
Market Trends: How does Esperion Therapeutics Inc. score in quality rankings2025 Key Highlights & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
What is the next catalyst for Esperion Therapeutics IncWeekly Investment Report & Expert Curated Trade Setups - baoquankhu1.vn
Weekly Trades: How does Esperion Therapeutics Inc. score in quality rankingsMarket Risk Report & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
Esperion Therapeutics Inc. (ESPR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Zacks Research Issues Optimistic Forecast for ESPR Earnings - MarketBeat
Zacks Research Analysts Reduce Earnings Estimates for ESPR - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Raised to "Buy" at Wall Street Zen - MarketBeat
How The New Price Target Is Shaping The Story For Esperion Therapeutics (ESPR) - Yahoo Finance
3,000,000 Shares in Esperion Therapeutics, Inc. $ESPR Bought by AIGH Capital Management LLC - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Analyst Downgrade: What are Esperion Therapeutics Incs technical support levelsInflation Watch & Free Reliable Trade Execution Plans - baoquankhu1.vn
Esperion Therapeutics general counsel sells $4.9k in stock By Investing.com - Investing.com Australia
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Esperion Therapeutics general counsel sells $4.9k in stock - Investing.com
Esperion Therapeutics warns of winter cholesterol risk - Traders Union
Is Esperion Therapeutics Inc. stock a falling knife or bargain buyJuly 2025 Update & Stepwise Trade Signal Guides - bollywoodhelpline.com
Winners Losers: Is Esperion Therapeutics Inc a defensive stockMarket Sentiment Report & Entry and Exit Point Strategies - baoquankhu1.vn
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap DownShould You Sell? - MarketBeat
What is HC Wainwright's Estimate for ESPR FY2025 Earnings? - MarketBeat
Esperion Seeks Acquisitions - marketscreener.com
How does Esperion Therapeutics Inc score in quality rankingsDip Buying & Safe Entry Trade Signal Reports - baoquankhu1.vn
Highs Report: What is Esperion Therapeutics Incs TAM Total Addressable MarketJuly 2025 Sector Moves & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
HC Wainwright Issues Optimistic Estimate for ESPR Earnings - MarketBeat
Esperion Therapeutics Faces Financial Challenges Amid Market Uncertainty - StocksToTrade
Esperion Therapeutics (NASDAQ:ESPR) Shares Down 6.3%Here's Why - MarketBeat
Esperion Projects FY2025 U.S. Net Product Sales Growth Of 35% To 38%; Stock Up - Nasdaq
Esperion Reports $156-$160 Million in 2025 Sales, Unveils Vision 2040 Strategy - Intellectia AI
Esperion Reports Significant Growth in Preliminary 2025 Financial Results and Unveils Vision 2040 Growth Strategy - Quiver Quantitative
Esperion reports $156 to $160 million in preliminary full-year 2025 U.S. net product sales - marketscreener.com
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Cholesterol drug maker lays 2040 plan as new pills target 60% LDL drop - Stock Titan
Why Esperion Therapeutics Inc stock attracts global investorsMarket Movers & Community Verified Trade Signals - moha.gov.vn
Esperion Therapeutics Stock Hits Near 1-Year High As Wall Street Sees Strong Risk-Reward Play On Demand For Cholesterol Drug - MSN
Can Esperion Therapeutics Inc. stock sustain institutional interest2025 Market Sentiment & AI Driven Price Predictions - Улправда
Will Esperion Therapeutics Inc. (0ET) stock beat growth indexesQuarterly Performance Summary & Trade Opportunity Analysis - ulpravda.ru
Is Esperion Therapeutics Inc. (0ET) stock considered safe havenJuly 2025 Chart Watch & Verified Momentum Stock Watchlist - ulpravda.ru
Merger Talk: Is Esperion Therapeutics Inc. (0ET) stock considered safe haven2025 Winners & Losers & Reliable Momentum Entry Alerts - Улправда
Esperion Therapeutics (NASDAQ:ESPR) Sets New 12-Month HighHere's Why - MarketBeat
Esperion Therapeutics gets Untitled Letter from FDA over Nexlizet ad - Medical Marketing and Media
How Esperion Therapeutics Inc. stock performs in rising dollar environmentQuarterly Profit Report & Technical Buy Zone Confirmations - Улправда
Free Technical Research Reports on Biotech Stocks -- Epizyme, Esperion Therapeutics, Exelixis, and Grifols - ADVFN
Will Esperion Therapeutics Inc. (0ET) stock outperform value peersVolume Profile Analysis & Double Digit Returns - Улправда
Esperion Sets Its Sights on New Areas While Maintaining Commitment to Cardiovascular Health - MedCity News
Esperion Therapeutics chief commercial officer sells $277 in stock - MSN
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
What analysts say about Esperion Therapeutics Inc stockMarket Volatility Update & Rapid Wealth Accumulation - earlytimes.in
Why Is Esperion Therapeutics Stock Sinking Premarket Today? - MSN
Esperion Therapeutics (NASDAQ:ESPR) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap UpWhat's Next? - MarketBeat
Is Esperion Therapeutics Inc a good long term investmentGlobal Trade Effects & Free Rapid Wealth Building - earlytimes.in
Esperion Therapeutics (NASDAQ:ESPR) Shares Down 4.8%Time to Sell? - MarketBeat
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
0.04%
0.55%
大文字化:
|
ボリューム (24 時間):